11 results about "IGF-Binding Proteins" patented technology

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

The present disclosure provides composition for use in treating disorders, such as eye disorders (e.g., disorders affecting Meibomian glands). Composition(s) for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGF1R. Such compositions may evade IGF binding proteins. Related methods, kits, and pharmaceutical compositions are also disclosed.

The present disclosure provides composition for use in treating disorders, such as eye disorders (e.g., disorders affecting Meibomian glands). Composition(s) for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGF1R. Such compositions may evade IGF binding proteins. Related methods, kits, and pharmaceutical compositions are also disclosed.

The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.

The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and / or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500 μg / Kg / day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and / or protection from circulatory collapse.

The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.

The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.

The present invention relates to methods for detecting the presence and / or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4) or ADAMTS9 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and / or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

The present disclosure relates to treatment of subpopulation of neonates for reducing the risk of IVH and / or severe IVH, such as grade 3 or 4 IVH by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding protein (such as IGFBP-3), for example as a complex, at a dose of 200-500µg / Kg / day. In a further aspect there is provided stabilisation of vital functions when hyperosmolarity occurs and / or protection from circulatory collapse.

The present invention relates to methods for detecting the presence and / or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4), ADAMTS9, ADAPT, ADAPTI, ADAPT-2, FIB-4 or Pro-C3 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and / or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.